ACADIA Pharmaceuticals (ACAD) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

ACADIA Pharmaceuticals (ACAD) overview

ACADIA Pharmaceuticals (ACAD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,072m and operating profit of USD 105m; the year-end share price was 26.71 USD and market capitalisation was USD 4,549m. ACADIA Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ACADIA Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,227mFY 2025
Share price26.71 USDFY 2025 year end
RevenueUSD 1,072mFY 2025
Operating profitUSD 105mFY 2025
Net earningsUSD 391mFY 2025
Market capitalisationUSD 4,549mFY 2025 year end

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals develops medicines for neurological and rare diseases. Its commercial products include NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE for Rett syndrome. The company also has research programs and product candidates for conditions including Alzheimer’s disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor and tardive dyskinesia.

Generate the ACADIA Pharmaceuticals report

ACADIA Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ACADIA Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on ACADIA Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.